[Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin].
Twenty-five patients with metastatic breast cancer who had failed with combination chemotherapies including adriamycin were treated with a combination of mitomycin C, methotrexate, and vincristine (MMV). MMC 5 mg/m2, methotrexate 18 mg/m2, vincristine 0.7 mg/m2 were given i.v. on days 1 and 8, and repeated every 21 days. Seven patients (28%) experienced a partial response: 7 maintained NC and 11 failed to respond (PD). Median duration of regression was 12 weeks. Median survival time in PR patients was one year and 3 months, contrary to 6 months in patients with NC or PD. This combination was well tolerated except thrombocytopenia in 5 patients.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D016685:Mitomycin; D014750:Vincristine; D004317:Doxorubicin; D008727:Methotrexate